Lung cancer specific peptides for targeted drug delivery and molecular imaging
US9387257B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 16, 2015 |
| Grant date | Jul 12, 2016 |
| Priority date | — |
| Expiry date | Feb 1, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2458/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A conjugate is disclosed. The conjugate comprises (a) an isolated or a synthetic targeting peptide of less than 15 amino acid residues in length, comprising an amino acid sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 1-8; and (b) a component conjugated to the targeting peptide, the component being selected from the group consisting of a drug delivery vehicle, an anti-cancer drug, a micelle, a nanoparticle, a liposome, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a cell, an imaging agent, and a labeling agent. Methods of treating lung cancer and detecting lung cancer cells are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.